Drugs / Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03222674 | Jul 2025 → Jun 2028 expected | acute myeloid leukemia | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03222674 ↗ |
| Modality | Cell therapy | “the patients' own T cells will be genetically modified with lentiviral vectors expressing chimeric antigen receptors” NCT03222674 ↗ |
| Target | CD33 | “The multi-CAR T cells recognize specific molecules such as CD33, CD38, CD123, CD56, MucI, and CLL1, which are often found expressed on the surface of AML cells.” NCT03222674 ↗ |
| Target | CD38 | “The multi-CAR T cells recognize specific molecules such as CD33, CD38, CD123, CD56, MucI, and CLL1, which are often found expressed on the surface of AML cells.” NCT03222674 ↗ |